Circulation: Heart Failure最新文献

筛选
英文 中文
Beyond Survival: Empowering Women by Enhancing Reproductive Health Education for Heart Transplant Recipients. 超越生存:通过加强对心脏移植受者的生殖健康教育来增强妇女的能力。
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-08-01 DOI: 10.1161/CIRCHEARTFAILURE.124.012085
Sophia Airhart, Catriona Bhagra
{"title":"Beyond Survival: Empowering Women by Enhancing Reproductive Health Education for Heart Transplant Recipients.","authors":"Sophia Airhart, Catriona Bhagra","doi":"10.1161/CIRCHEARTFAILURE.124.012085","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.012085","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e012085"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial. 早期和亚临床肥厚型心肌病患者的生活质量和运动能力:VANISH 试验的二次分析。
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-08-01 DOI: 10.1161/CIRCHEARTFAILURE.124.011663
Catherine G Ireland, Danielle S Burstein, Sharlene M Day, Anna Axelsson Raja, Mark W Russell, Kenneth G Zahka, Alexandre Pereira, Charles E Canter, Richard G Bach, Matthew T Wheeler, Joseph W Rossano, Anjali T Owens, Henning Bundgaard, Luisa Mestroni, Matthew R G Taylor, Amit R Patel, Ivan Wilmot, Jonathan H Soslow, Jason R Becker, Ilya Giverts, E John Orav, Brian Claggett, Kimberly Y Lin, Carolyn Y Ho
{"title":"Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial.","authors":"Catherine G Ireland, Danielle S Burstein, Sharlene M Day, Anna Axelsson Raja, Mark W Russell, Kenneth G Zahka, Alexandre Pereira, Charles E Canter, Richard G Bach, Matthew T Wheeler, Joseph W Rossano, Anjali T Owens, Henning Bundgaard, Luisa Mestroni, Matthew R G Taylor, Amit R Patel, Ivan Wilmot, Jonathan H Soslow, Jason R Becker, Ilya Giverts, E John Orav, Brian Claggett, Kimberly Y Lin, Carolyn Y Ho","doi":"10.1161/CIRCHEARTFAILURE.124.011663","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011663","url":null,"abstract":"<p><strong>Background: </strong>The health-related quality of life (HRQOL) and cardiopulmonary exercise testing (CPET) performance of individuals with subclinical and early stage hypertrophic cardiomyopathy (HCM) have not been systematically studied. Improved understanding will inform the natural history of HCM and factors influencing well-being.</p><p><strong>Methods: </strong>VANISH trial (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) participants with early stage sarcomeric HCM (primary analysis cohort) and subclinical HCM (sarcomere variant without left ventricular hypertrophy comprising the exploratory cohort) who completed baseline and year 2 HRQOL assessment via the pediatric quality of life inventory and CPET were studied. Metrics correlating with baseline HRQOL and CPET performance were identified. The impact of valsartan treatment on these measures was analyzed in the early stage cohort.</p><p><strong>Results: </strong>Two hundred participants were included: 166 with early stage HCM (mean age, 23±10 years; 40% female; 97% White; and 92% New York Heart Association class I) and 34 subclinical sarcomere variant carriers (mean age, 16±5 years; 50% female; and 100% White). Baseline HRQOL was good in both cohorts, although slightly better in subclinical HCM (composite pediatric quality of life score 84.6±10.6 versus 90.2±9.8; <i>P</i>=0.005). Both cohorts demonstrated mildly reduced functional status (mean percent predicted peak oxygen uptake 73±16 versus 78±12 mL/kg per minute; <i>P</i>=0.18). Percent predicted peak oxygen uptake and peak oxygen pulse correlated with HRQOL. Valsartan improved physical HRQOL in early stage HCM (adjusted mean change in pediatric quality of life score +4.1 versus placebo; <i>P</i>=0.01) but did not significantly impact CPET performance.</p><p><strong>Conclusions: </strong>Functional capacity can be impaired in young, healthy people with early stage HCM, despite New York Heart Association class I status and good HRQOL. Peak oxygen uptake was similarly decreased in subclinical HCM despite normal left ventricular wall thickness and excellent HRQOL. Valsartan improved physical pediatric quality of life scores but did not significantly impact CPET performance. Further studies are needed for validation and to understand how to improve patient experience.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov; Unique identifier: NCT01912534.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011663"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trimethylamine N-Oxide and Related Gut Microbe-Derived Metabolites and Incident Heart Failure Development in Community-Based Populations. 社区人群中的三甲胺 N-氧化物和相关肠道微生物衍生代谢物与心力衰竭发病率。
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-08-01 Epub Date: 2024-08-09 DOI: 10.1161/CIRCHEARTFAILURE.124.011569
W H Wilson Tang, Rozenn N Lemaitre, Paul N Jensen, Meng Wang, Zeneng Wang, Xinmin S Li, Ina Nemet, Yujin Lee, Heidi T M Lai, Marcia C de Oliveira Otto, Amanda M Fretts, Nona Sotoodehnia, Joseph A DiDonato, Fredrik Bäckhed, Bruce M Psaty, David S Siscovick, Matthew J Budoff, Dariush Mozaffarian, Stanley L Hazen
{"title":"Trimethylamine <i>N</i>-Oxide and Related Gut Microbe-Derived Metabolites and Incident Heart Failure Development in Community-Based Populations.","authors":"W H Wilson Tang, Rozenn N Lemaitre, Paul N Jensen, Meng Wang, Zeneng Wang, Xinmin S Li, Ina Nemet, Yujin Lee, Heidi T M Lai, Marcia C de Oliveira Otto, Amanda M Fretts, Nona Sotoodehnia, Joseph A DiDonato, Fredrik Bäckhed, Bruce M Psaty, David S Siscovick, Matthew J Budoff, Dariush Mozaffarian, Stanley L Hazen","doi":"10.1161/CIRCHEARTFAILURE.124.011569","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011569","url":null,"abstract":"<p><strong>Background: </strong>Growing evidence indicates that trimethylamine <i>N</i>-oxide, a gut microbial metabolite of dietary choline and carnitine, promotes both cardiovascular disease and chronic kidney disease risk. It remains unclear how circulating concentrations of trimethylamine <i>N</i>-oxide and its related dietary and gut microbe-derived metabolites (choline, betaine, carnitine, γ-butyrobetaine, and crotonobetaine) affect incident heart failure (HF).</p><p><strong>Methods: </strong>We evaluated 11 768 participants from the Cardiovascular Health Study and the Multi-Ethnic Study of Atherosclerosis with serial measures of metabolites. Cox proportional hazard models were used to examine the associations between metabolites and incident HF, adjusted for cardiovascular disease risk factors.</p><p><strong>Results: </strong>In all, 2102 cases of HF occurred over a median follow-up of 15.9 years. After adjusting for traditional risk factors, higher concentrations of trimethylamine <i>N</i>-oxide (hazard ratio, 1.15 [95% CI, 1.09-1.20]; <i>P</i><0.001), choline (hazard ratio, 1.44 [95% CI, 1.26-1.64]; <i>P</i><0.001), and crotonobetaine (hazard ratio, 1.24 [95% CI, 1.16-1.32]; <i>P</i><0.001) were associated with increased risk for incident HF. After further adjustment for renal function (potential confounder or mediator), these associations did not reach Bonferroni-corrected statistical significance (<i>P</i>=0.01, 0.049, and 0.006, respectively). Betaine and carnitine were nominally associated with a higher incidence of HF (<i>P</i><0.05). In exploratory analyses, results were similar for subtypes of HF based on left ventricular ejection fraction, and associations appeared generally stronger among Black and Hispanic/Latino versus White adults, although there were no interactions for any metabolites with race.</p><p><strong>Conclusions: </strong>In this pooled analysis of 2 well-phenotyped, diverse, community-based cohorts, circulating concentrations of gut microbe-derived metabolites such as trimethylamine <i>N</i>-oxide, choline, and crotonobetaine were independently associated with a higher risk of developing HF.</p><p><strong>Registration: </strong>URL: https://www.clinicaltrials.gov/; Unique identifiers: NCT00005133 and NCT00005487.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011569"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Home Hemodynamic Monitoring to Guide Reduction of Persistently High Pulmonary Artery Pressures in Chronic Heart Failure. 家庭血流动力学监测指导降低慢性心力衰竭患者持续过高的肺动脉压力。
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-08-01 Epub Date: 2024-07-11 DOI: 10.1161/CIRCHEARTFAILURE.124.011946
Stacy Tsai, Natalie Castillo, Lynne Warner Stevenson, Sandip Zalawadiya
{"title":"Home Hemodynamic Monitoring to Guide Reduction of Persistently High Pulmonary Artery Pressures in Chronic Heart Failure.","authors":"Stacy Tsai, Natalie Castillo, Lynne Warner Stevenson, Sandip Zalawadiya","doi":"10.1161/CIRCHEARTFAILURE.124.011946","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011946","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011946"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antithrombotic Therapy for Mechanical Circulatory Support: Time to Throw the Baby (Warfarin) Out With the Bathwater (Aspirin)? 机械循环支持的抗血栓治疗:是时候把婴儿(华法林)和洗澡水(阿司匹林)一起扔掉了吗?
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-08-01 Epub Date: 2024-07-25 DOI: 10.1161/CIRCHEARTFAILURE.124.011568
Jane T Kelleher, Michael M Givertz
{"title":"Antithrombotic Therapy for Mechanical Circulatory Support: Time to Throw the Baby (Warfarin) Out With the Bathwater (Aspirin)?","authors":"Jane T Kelleher, Michael M Givertz","doi":"10.1161/CIRCHEARTFAILURE.124.011568","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011568","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011568"},"PeriodicalIF":7.8,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141757439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Donation After Circulatory Death Heart Transplant: Current State and Future Directions. 循环死亡心脏移植后的捐献:现状与未来方向。
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-07-01 Epub Date: 2024-06-20 DOI: 10.1161/CIRCHEARTFAILURE.124.011678
Amrin Kharawala, Sanjana Nagraj, Jiyoung Seo, Sumant Pargaonkar, Mayuko Uehara, Daniel J Goldstein, Snehal R Patel, Daniel B Sims, Ulrich P Jorde
{"title":"Donation After Circulatory Death Heart Transplant: Current State and Future Directions.","authors":"Amrin Kharawala, Sanjana Nagraj, Jiyoung Seo, Sumant Pargaonkar, Mayuko Uehara, Daniel J Goldstein, Snehal R Patel, Daniel B Sims, Ulrich P Jorde","doi":"10.1161/CIRCHEARTFAILURE.124.011678","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011678","url":null,"abstract":"<p><p>Orthotopic heart transplant is the gold standard therapeutic intervention for patients with end-stage heart failure. Conventionally, heart transplant has relied on donation after brain death for organ recovery. Donation after circulatory death (DCD) is the donation of the heart after confirming that circulatory function has irreversibly ceased. DCD-orthotopic heart transplant differs from donation after brain death-orthotopic heart transplant in ways that carry implications for widespread adoption, including differences in organ recovery, storage and ethical considerations surrounding normothermic regional perfusion with DCD. Despite these differences, DCD has shown promising early outcomes, augmenting the donor pool and allowing more individuals to benefit from orthotopic heart transplant. This review aims to present the current state and future trajectory of DCD-heart transplant, examine key differences between DCD and donation after brain death, including clinical experiences and innovations in methodologies, and address the ongoing ethical challenges surrounding the new frontier in heart transplant with DCD donors.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011678"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixed Shock Complicating Cardiogenic Shock: A Corollary or a Ramification? 混合性休克并发心源性休克:是必然结果还是后遗症?
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-07-01 Epub Date: 2024-07-09 DOI: 10.1161/CIRCHEARTFAILURE.124.011902
Anju Bhardwaj, Mrudula Munagala
{"title":"Mixed Shock Complicating Cardiogenic Shock: A Corollary or a Ramification?","authors":"Anju Bhardwaj, Mrudula Munagala","doi":"10.1161/CIRCHEARTFAILURE.124.011902","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011902","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011902"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overexpression of ATP5F1A in Cardiomyocytes Promotes Cardiac Reverse Remodeling. 心肌细胞中 ATP5F1A 的过表达会促进心脏反向重塑
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-07-01 Epub Date: 2024-06-24 DOI: 10.1161/CIRCHEARTFAILURE.123.011504
Mengda Xu, Hang Zhang, Yuan Chang, Xiumeng Hua, Xiao Chen, Yixuan Sheng, Dan Shan, Mengni Bao, Shengshou Hu, Jiangping Song
{"title":"Overexpression of <i>ATP5F1A</i> in Cardiomyocytes Promotes Cardiac Reverse Remodeling.","authors":"Mengda Xu, Hang Zhang, Yuan Chang, Xiumeng Hua, Xiao Chen, Yixuan Sheng, Dan Shan, Mengni Bao, Shengshou Hu, Jiangping Song","doi":"10.1161/CIRCHEARTFAILURE.123.011504","DOIUrl":"10.1161/CIRCHEARTFAILURE.123.011504","url":null,"abstract":"<p><strong>Background: </strong>The mechanism of cardiac reverse remodeling (CRR) mediated by the left ventricular assist device remains unclear. This study aims to identify the specific cell type responsible for CRR and develop the therapeutic target that promotes CRR.</p><p><strong>Methods: </strong>The nuclei were extracted from the left ventricular tissue of 4 normal controls, 4 CRR patients, and 4 no cardiac reverse remodeling patients and then subjected to single-nucleus RNA sequencing for identifying key cell types responsible for CRR. Gene overexpression in transverse aortic constriction and dilated cardiomyopathy heart failure mouse model (C57BL/6J background) and pathological staining were performed to validate the results of single-nucleus RNA sequencing.</p><p><strong>Results: </strong>Ten cell types were identified among 126 156 nuclei. Cardiomyocytes in CRR patients expressed higher levels of <i>ATP5F1A</i> than the other 2 groups. The macrophages in CRR patients expressed more anti-inflammatory genes and functioned in angiogenesis. Endothelial cells that elevated in no cardiac reverse remodeling patients were involved in the inflammatory response. Echocardiography showed that overexpressing <i>ATP5F1A</i> through cardiomyocyte-specific adeno-associated virus 9 demonstrated an ability to improve heart function and morphology. Pathological staining showed that overexpressing <i>ATP5F1A</i> could reduce fibrosis and cardiomyocyte size in the heart failure mouse model.</p><p><strong>Conclusions: </strong>The present results of single-nucleus RNA sequencing and heart failure mouse model indicated that <i>ATP5F1A</i> could mediate CRR and supported the development of therapeutics for overexpressing <i>ATP5F1A</i> in promoting CRR.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011504"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11244755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SUSTAINing the Care of Patients With Advanced Heart Failure by Supporting Family Caregivers. 通过支持家庭护理人员继续护理晚期心力衰竭患者。
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-07-01 Epub Date: 2024-06-24 DOI: 10.1161/CIRCHEARTFAILURE.124.011874
Martha Abshire Saylor, Colleen K McIlvennan
{"title":"SUSTAINing the Care of Patients With Advanced Heart Failure by Supporting Family Caregivers.","authors":"Martha Abshire Saylor, Colleen K McIlvennan","doi":"10.1161/CIRCHEARTFAILURE.124.011874","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011874","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011874"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter by ten Berg et al Regarding Article, "Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry". ten Berg 等人就文章 "心源性休克患者血管活性支持总量和死亡率的早期序列评估:重症心脏病学试验网络注册的启示 "的来信。
IF 7.8 1区 医学
Circulation: Heart Failure Pub Date : 2024-07-01 Epub Date: 2024-06-20 DOI: 10.1161/CIRCHEARTFAILURE.124.011970
Sanne Ten Berg, Luuk Otterspoor, José P S Henriques
{"title":"Letter by ten Berg et al Regarding Article, \"Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry\".","authors":"Sanne Ten Berg, Luuk Otterspoor, José P S Henriques","doi":"10.1161/CIRCHEARTFAILURE.124.011970","DOIUrl":"10.1161/CIRCHEARTFAILURE.124.011970","url":null,"abstract":"","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011970"},"PeriodicalIF":7.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信